BMEA
Biomea Fusion, Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.01
+4.97%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 93.0K | 1.4M | — | — | — |
| Gross Profit | (93.0K) | (1.4M) | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 40.8M | 62.0M | 118.1M | 102.5M | 62.7M |
| SG&A Expense | 15.1M | 19.3M | 26.0M | 23.6M | 20.9M |
| General & Admin Expense | 15.1M | 19.3M | 26.0M | 23.6M | 20.9M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 2.1M | (1.4M) | — | — | — |
| Total Operating Expenses | 58.0M | 79.9M | 144.1M | 126.1M | 83.6M |
| Cost and Expenses | 58.1M | 81.3M | 144.1M | 126.1M | 83.6M |
| Operating Income (EBIT) | (58.1M) | (81.3M) | (144.1M) | (126.1M) | (83.6M) |
| Non-Operating | |||||
| Interest Income | 1.6M | 1.9M | 5.6M | 8.9M | 1.8M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 1.6M | 1.9M | 5.6M | 8.9M | 1.8M |
| Other Non-Op Income/Expense | 25.5M | 19.5M | 5.6M | 8.9M | 1.8M |
| Non-Operating Income (excl Interest) | (23.3M) | (19.5M) | (5.6M) | (8.9M) | (1.8M) |
| EBT (Pre-Tax Income) | (32.5M) | (61.8M) | (138.4M) | (117.3M) | (81.8M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (32.5M) | (61.8M) | (138.4M) | (117.3M) | (81.8M) |
| Earnings from Cont. Ops | (32.5M) | (61.8M) | (138.4M) | (117.3M) | (81.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (32.5M) | (61.8M) | (138.4M) | (117.3M) | (81.8M) |
| Per Share | |||||
| Basic EPS | ($0.50) | ($1.18) | ($3.83) | ($3.44) | ($2.80) |
| Diluted EPS | ($0.50) | ($1.18) | ($3.83) | ($3.44) | ($2.80) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 72.4M | 52.2M | 36.1M | 34.1M | 29.3M |
| Diluted Shares Outstanding | 72.4M | 52.2M | 36.1M | 34.1M | 29.3M |
| Profitability Metrics | |||||
| EBITDA | (34.2M) | (60.4M) | (136.7M) | (115.7M) | (81.1M) |
| D&A | 520.0K | 1.4M | 1.7M | 1.5M | 691.0K |
| EBIT | (34.7M) | (61.8M) | (138.4M) | (117.3M) | (81.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026